10:31 ETBronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsightprnewswire·Aug 13 at 09:31 AMARMP-12.82%INSM-4.27%
Armata Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.51 MEarnings Watch·Aug 12 at 03:53 PMARMP-12.82%
Armata swings to FY26 Q2 net income of $74.14 million; operating loss widens to $10.31 millionPUBT·Aug 12 at 03:06 PMARMP-12.82%
Top Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watchrttnews·Jul 20 at 10:01 PMARMP-12.82%ZYBT+2.16%
Armata Shares Surge on Progress Toward Late-Stage Trial of Superbug TreatmentMorningStar·Jul 20 at 10:29 AMARMP-12.82%
07:00 ETArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02prnewswire·Jul 20 at 06:01 AMARMP-12.82%
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia | ARMP Stock NewsStockTitan·Jul 12 at 10:00 PMARMP-12.82%
